Table of Contents
ISRN Psychiatry
Volume 2012, Article ID 703751, 5 pages
http://dx.doi.org/10.5402/2012/703751
Clinical Study

Evaluation of Efficacy, Safety, and Cognitive Profile of Amisulpride Per Se and Its Comparison with Olanzapine in Newly Diagnosed Schizophrenic Patients in an 8-Week, Double-Blind, Single-Centre, Prospective Clinical Trial

1Department of Pharmacology, MGM Medical College, Indore 452001, India
2Department of Psychiatry, MY Hospital, Indore 452001, India

Received 23 November 2011; Accepted 29 December 2011

Academic Editors: A. Michael and A. Weizman

Copyright © 2012 Ganesh R. Pawar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Addington, D. Addington, and E. Maticka-Tyndale, “Cognitive functioning and positive and negative symptoms in schizophrenia,” Schizophrenia Research, vol. 5, no. 2, pp. 123–134, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. S. R. McGurk, P. J. Moriarty, P. D. Harvey, M. Parrella, L. White, and K. L. Davis, “The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia,” Schizophrenia Research, vol. 42, no. 1, pp. 47–55, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. L. A. Flashman and M. F. Green, “Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment,” Psychiatric Clinics of North America, vol. 27, no. 1, pp. 1–18, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. J. Saykin, R. C. Gur, R. E. Gur et al., “Neuropsychological function in schizophrenia: selective impairment in memory and learning,” Archives of General Psychiatry, vol. 48, no. 7, pp. 618–624, 1991. View at Google Scholar · View at Scopus
  5. M. F. Green, “What are the functional consequences of neurocognitive deficits in schizophrenia?” The American Journal of Psychiatry, vol. 153, no. 3, pp. 321–330, 1996. View at Google Scholar · View at Scopus
  6. R. J. Heslegrave, A. G. Awad, and L. N. P. Voruganti, “The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia,” Journal of Psychiatry and Neuroscience, vol. 22, no. 4, pp. 235–243, 1997. View at Google Scholar · View at Scopus
  7. S. Sevy and M. Davidson, “The cost of cognitive impairment in schizophrenia,” Schizophrenia Research, vol. 17, no. 1, pp. 1–3, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. A. L. Mishara and T. E. Goldberg, “A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book,” Biological Psychiatry, vol. 55, no. 10, pp. 1013–1022, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. Tarsey, “Neuroleptic induced extra pyramidal reactions: classification, description and diagnosis,” Clinical Neuropharmacology, vol. 6, supplement 1, pp. S9–S26, 1983. View at Google Scholar
  10. C. D. Marsden, R. H. S. Mindham, and A. V. P. Mackay, “Extrapyramidal movement disorders produced by antipsychotic drugs,” in The Psychopharmacology and Drug Treatment of Schizophrenia, P. B. Bradley and S. R. Hirsch, Eds., pp. 340–402, OUP, Oxford, UK, 1986. View at Google Scholar
  11. J. M. Kane and J. M. Smith, “Tardive dyskinesia: prevalence and risk factors, 1959 to 1979,” Archives of General Psychiatry, vol. 39, no. 4, pp. 473–481, 1982. View at Google Scholar · View at Scopus
  12. D. Tarsy, R. J. Baldessarini, and F. I. Tarazi, “Effects of newer antipsychotics on extrapyramidal function,” CNS Drugs, vol. 16, no. 1, pp. 23–45, 2002. View at Google Scholar · View at Scopus
  13. R. S. E. Keefe, S. G. Silva, D. O. Perkins, and J. A. Lieberman, “The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis,” Schizophrenia Bulletin, vol. 25, no. 2, pp. 201–222, 1999. View at Google Scholar · View at Scopus
  14. W. T. Carpenter and J. M. Gold, “Another view of therapy for cognition in schizophrenia,” Biological Psychiatry, vol. 51, no. 12, pp. 969–971, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Schoemaker, Y. Claustre, D. Fage et al., “Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity,” Journal of Pharmacology and Experimental Therapeutics, vol. 280, no. 1, pp. 83–97, 1997. View at Google Scholar · View at Scopus
  16. S. Leucht, G. Pitschel-Walz, R. R. Engel, and W. Kissling, “Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials,” The American Journal of Psychiatry, vol. 159, no. 2, pp. 180–190, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. P. J. Tyson, K. H. Roberts, and A. M. Mortimer, “Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors?” International Journal of Neuroscience, vol. 114, no. 6, pp. 593–611, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. G. Vaiva, P. Thomas, P. M. Llorca et al., “SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome,” Psychiatry Research, vol. 115, no. 1-2, pp. 37–48, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. F. P. Bymaster, D. O. Calligaro, J. F. Falcone et al., “Radioreceptor binding profile of the atypical antipsychotic olanzapine,” Neuropsychopharmacology, vol. 14, no. 2, pp. 87–96, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. P. V. Tran, M. A. Dellva, G. D. Tollefson, C. M. Beasley, J. H. Potvin, and G. M. Kiesler, “Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia,” Journal of Clinical Psychiatry, vol. 58, no. 5, pp. 205–211, 1997. View at Google Scholar · View at Scopus
  21. R. M. Bilder, R. S. Goldman, J. Volavka et al., “Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder,” The American Journal of Psychiatry, vol. 159, no. 6, pp. 1018–1028, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Sharma, C. Hughes, W. Soni, and V. Kumari, “Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia,” Psychopharmacology, vol. 169, no. 3-4, pp. 398–403, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. E. Overall and D. R. Gorham, “The brief psychiatric rating scale,” Psychological Reports, vol. 10, pp. 799–812, 1962. View at Google Scholar
  24. S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987. View at Google Scholar · View at Scopus
  25. M. R. Munetz and S. Benjamin, “How to examine patients using the abnormal involuntary movement scale,” Hospital and Community Psychiatry, vol. 39, no. 11, pp. 1172–1177, 1988. View at Google Scholar · View at Scopus
  26. E. De Renzi and P. Faglioni, “The token test: normative data and screening power of a shortened version of the token test,” Cortex, vol. 3, pp. 327–342, 1978. View at Google Scholar
  27. J. R. Stroop, “Studies of interference in serial verbal reactions,” Journal of Experimental Psychology, vol. 18, no. 6, pp. 643–662, 1935. View at Publisher · View at Google Scholar · View at Scopus
  28. S. L. Rao, D. K. Subbakrishna, and K. Gopukumar, NIMHANS Neuropsychological Battery, NIMHANS Publications, Bangalore, India, 2004.
  29. M. D. Lezak, Neuropsychological Assessment, Oxford University Press, New York, NY, USA, 3rd edition, 1995.
  30. F. W. Doss, “The effect of antipsychotic drugs on body weight: a retrospective review,” Journal of Clinical Psychiatry, vol. 40, no. 12, pp. 528–530, 1979. View at Google Scholar · View at Scopus
  31. D. B. Allison, J. L. Mentore, M. Heo et al., “Antipsychotic-induced weight gain: a comprehensive research synthesis,” The American Journal of Psychiatry, vol. 156, no. 11, pp. 1686–1696, 1999. View at Google Scholar · View at Scopus
  32. P. S. Masand, “Weight gain associated with atypical antipsychotics,” Journal of Psychotic Disorder, vol. 2, pp. 4–6, 1998. View at Google Scholar
  33. N. Sussman, “Review of atypical antipsychotics and weight gain,” Journal of Clinical Psychiatry, vol. 62, no. 23, pp. 5–12, 2001. View at Google Scholar · View at Scopus
  34. S. Gupta, T. Droney, S. Al-Samarrai, P. Keller, and B. Frank, “Olanzapine: weight gain and therapeutic efficacy,” Journal of Clinical Psychopharmacology, vol. 19, no. 3, pp. 273–276, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. U. Eder, B. Mangweth, C. Ebenbichler et al., “Association of olanzapine-induced weight gain with an increase in body fat,” The American Journal of Psychiatry, vol. 158, no. 10, pp. 1719–1722, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. D. N. Osser, D. M. Najarian, and R. L. Dufresne, “Olanzapine increases weight and serum triglyceride levels,” Journal of Clinical Psychiatry, vol. 60, no. 11, pp. 767–770, 1999. View at Google Scholar · View at Scopus
  37. J. G. Bernstein, “Psychotropic drug induced weight gain: mechanisms and management,” Clinical Neuropharmacology, vol. 11, no. 1, pp. S194–S206, 1988. View at Google Scholar · View at Scopus
  38. M. Wagner, B. B. Quednow, J. Westheide, T. E. Schlaepfer, W. Maier, and K. U. Kühn, “Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride,” Neuropsychopharmacology, vol. 30, no. 2, pp. 381–390, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. E. Stip, G. J. Remington, S. M. Dursun et al., “A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine,” Journal of Clinical Psychopharmacology, vol. 23, no. 4, pp. 400–404, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. B. Morel, Traité des Maladies Mentales, vol. 2, Masson, Paris, France, 2nd edition, 1860.
  41. H. Y. Meltzer and S. R. McGurk, “The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia,” Schizophrenia Bulletin, vol. 25, no. 2, pp. 233–255, 1999. View at Google Scholar · View at Scopus